Sernova Biotherapeutics Inc
SVA.TO
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -15.49% | -17.21% | -18.78% | -15.99% | -9.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.18% | -53.89% | -54.10% | -56.60% | -51.44% |
| Operating Income | 50.18% | 53.89% | 54.10% | 56.60% | 51.44% |
| Income Before Tax | 44.80% | 56.14% | 52.68% | 53.89% | 48.47% |
| Income Tax Expenses | -317.75% | -635.42% | 21.57% | -- | -- |
| Earnings from Continuing Operations | 45.42% | 56.41% | 52.66% | 53.71% | 48.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.42% | 56.41% | 52.66% | 53.71% | 48.35% |
| EBIT | 50.18% | 53.89% | 54.10% | 56.60% | 51.44% |
| EBITDA | 50.28% | 54.07% | 54.30% | 56.71% | 51.68% |
| EPS Basic | 48.70% | 59.09% | 56.06% | 56.83% | 50.55% |
| Normalized Basic EPS | 47.59% | 58.50% | 55.88% | 56.85% | 50.71% |
| EPS Diluted | 48.70% | 59.09% | 56.06% | 56.83% | 50.55% |
| Normalized Diluted EPS | 47.59% | 58.50% | 55.88% | 56.85% | 50.71% |
| Average Basic Shares Outstanding | 5.30% | 5.60% | 6.95% | 7.27% | 5.24% |
| Average Diluted Shares Outstanding | 5.30% | 5.60% | 6.95% | 7.27% | 5.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |